CN EN

news

Shanghai, April 18, 2019 – Sundia will hold a session conference with Oscotec Inc. Bridge Biotherapeutics, Inc. and U-Chem at BioKorea in the morning of April 18th, 2019. We invited Dr. Jung-Ho Kim ,(Executive Director, CTO)of Oscotec Inc. and Dr. Sang Uk Kang,( SVP, Head of R&D) of Bridge Biotherapeutics, Inc. to share their views about how CRO companies can help pharmaceutical companies to better and faster get approved on IND Filing. We welcome you to participate in and discuss with us.

Date: Wednesday,April 18th 9:00~12:00,2019

Room: 301


Partnering to success on IND filing

09:00

A Start up’s Approach from Discovery to Development

  1. Jung-Ho Kim , Executive Director, CTO.   Oscotec Inc.

09:45

Drug Development Strategy in NRDO Biotech Company

  1. Sang Uk Kang, Ph.D., SVP, Head of R&D.  Bridge Biotherapeutics, Inc.

10:30

Coffee break

10:45

Points ofConsideration to US FDA IND in CMC

Dr. Hui-Yi Shiao, Director, Regulatory Affair. Sundia MediTech Company, Ltd.

11:15

Panel Discussion

  1. Jung-Ho Kim, Dr. Sang Uk Kang,  Dr. Hui-Yi Shiao,  David Kwon

11:45

Q&A

Also we will exhibit from Apr 17th to 19th. Our booth number is #K22.

Venue: COEX, Seoul,Korea

To make an appointment, please contact us via email info@sundia.com.

Find more information at http://www.biokorea.org/program/conference_02asp.


Register Now!
Webinar: New Modality - Peptides Innovations and a Comprehensive Synthetic Peptide Drug Discovery Platform
June 19, 2024 at 10am ET / 07am PT / 04pm CET
View more
0.163554s
We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all